FDA Approves uptravi, and actelion's PAH camp will take another big step

Source: China Council for the promotion of drugs 2015-12-23 actelion has been committed to filling this gap since the sales volume of its elderly pulse hypertension (PAH) drug traceer continued to decline Now the good news is finally coming FDA approved uptravi on the 21st to slow the disease progression of PAH patients and reduce the risk of hospitalization It is said that the company is expected to launch the drug in the United States in early 2016 The approval is based on data from the III phase of 1156 patients The study shows that the drug reduces the incidence rate / mortality by 39% compared with placebo Common adverse reactions include headache, diarrhea, nausea, chin pain, vomiting, extreme pain, muscle pain, nasopharyngitis and blushing Actelion's existing basic treatment drugs opsumit and late treatment drugs veletri and uptravi will be used between the two drugs, and it is expected to recover traceer's sales decline under the impact of generic drugs "Actelion now has an unparalleled range of PAH drugs that provide a combination of long-term efficacy, safety and convenience for the continuous care of PAH patients." Jean Paul clozel, President of actelion, said in a statement Actelion was able to remain robust as Tracleer sales fell thanks to opsumit In the third quarter, traceer's sales decreased by 60 million to CHF 289 million, down 17% year-on-year, while opsumit's sales continued to rise, from CHF 58 million to CHF 147 million, filling the gap in sales and generating a surplus The momentum of the new drug launch is enough to prompt clozel to claim that its company does not need M & A, even though actelion has appeared on the M & a topic list as an acquirer or acquiree in the past In September, actelion failed to acquire ZS Pharma, which eventually fell into AstraZeneca's hands In June, there was a rumor that shire, a Dublin based drugmaker, intended to merge with actelion Now, shire seems to shift its target and is working to acquire baxalta And with uptravi joining the PAH camp, Bayer needs to be careful The German drugmaker has incorporated its PAH drug adempas into one of five potential drugs, which it expects to consolidate its position in the pharmaceutical sector in the next few years Original link: http://